Agenda

The Cell & Gene Meeting on the Mesa is a three-day conference combining discussions between key opinion leaders, senior executives and top academic researchers. The program also includes 60+ presentations by the field’s most promising companies and poster abstracts by 35 leading scientists from around the globe.

See the companies and speakers who presented at the 2016 meeting below. Check back in the future for updates on the 2017 program!

Quick Links

WEBCASTAGENDA SPONSORS

CGMOM16-Agenda-Day1-495x105

7:00am – 9:30am | REGISTRATION AND BREAKFAST
Sponsored by Cryoport
7:15am – 8:45am | CONCURRENT WORKSHOPS

DOING BUSINESS IN JAPAN WORKSHOP

Magnolia Room | 7:15am – 8:45am
In Partnership with the Forum for Innovative Regenerative Medicine (FIRM)

DOING BUSINESS IN JAPAN WORKSHOP
Implications of the New Regulatory Framework
Japan has the most ambitious regulatory system in the world and is the best country to start your business in the field of regenerative medicine. Industries in Japan, including pharmas, CMOs and CROs are seeking opportunities to collaborate with ARM member companies. This session will address an overview of the new regulatory framework for a better understanding of the system in Japan.

Workshop Chair:
Kunihiko Suzuki, Vice Chairman, Forum for Innovative Regenerative Medicine (FIRM); Member, Board of Directors and Vice Chairman, MEDINET Co.

7:15am – 7:20am | Greeting
Speaker:
Yuzo Toda, Chairman, Forum for Innovative Regenerative Medicine (FIRM); Senior Executive VP and Chief Technical Officer, Director, FUJIFILM Corporation

7:20am – 7:45am | New Era of Regenerative Medicine
Speaker:
Hidetaka Nishimura, Director, Bio-Industry Division, Ministry of Economy, Trade and Industry (METI)

7:45am – 8:10am | Securing Quality, Safety and Efficacy for Regenerative Medical Products
Speaker:
Soichiro Isobe, Ph.D., Director, Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare (MHLW), Government of Japan

8:10am – 8:35am | Consultation and Review Pathway for Regenerative Medical Products in Japan
Speaker:
Yoshiaki Maruyama, Ph.D., Review Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA)

8:35am – 8:45am | Closing Remarks
Speaker:
Akihiko Iwai, Ph.D., Vice Chairman, Forum for Innovative Regenerative Medicine (FIRM); Divisional SVP, Research Portfolio and Science, Drug Discovery Research, Astellas Pharma

GENE THERAPY MANUFACTURING WORKSHOP

Learning Theater | 7:15am – 8:45am
Sponsored by Brammer Bio and MaxCyte

GENE THERAPY MANUFACTURING WORKSHOP
Strategies for BioManufacturing Viral-based Gene Therapy Vectors – Early-Stage Development Through Clinical Production

Workshop Topics to Include:

  • Manufacturing in early development – construct optimization and comparative analysis, assay development, validation
  • AAV and lentivirus process development – scale-up, quality and the need for standards
  • Establishing novel stable producer cell lines – strategies and current state of the science
  • In house versus out-sourced bioproduction – how and when to transfer the technology, best practices for coordination and demonstration of comparability, advantages and disadvantages of outsource vs. in-house manufacturing, current problems with the supply chain, current efforts of / by therapeutic companies to secure short, mid and long term supply
  • Toward large scale clinical and commercial production – scale up, vector analytics, COGS, regulatory requirements; compare and contrast requirements for ‘direct use’ v ‘use as reagent in cell-based gene therapy’
  • How (if at all) are gene editing technologies disruptive to the use of viral-based gene vectors? What should therapeutics companies be thinking about? What should vector manufacturing firms be preparing for/thinking about?

Welcome Remarks / Introduction:
Robert Preti, Ph.D., Chairman, Alliance for Regenerative Medicine (ARM); President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences

Chair:
Jessica Carmen, Ph.D., Director of Business Development, Cellular Therapy Partnerships, MaxCyte

Speakers:
James Brown, Ph.D., VP, Corporate Development, Aldevron
Matthew Caple, VP, Site Operations, Brammer Bio
Mike Kelly,
Director, Asset Leadership and Portfolio Management, Gene Therapy, Biogen
Michael Roberts, Ph.D.,
Chief Scientific Officer, Synpromics

9:00am | GENERAL SESSION AND PARTNERING OPENS
9:00am – 9:15am WELCOME REMARKS {Ballroom 1}
Speaker:
Robert Preti, Ph.D., Chairman, Alliance for Regenerative Medicine (ARM); President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences
9:15am – 10:15am PLENARY SESSION: MEASURING PROGRESS IN CELL-BASED IMMUNO-ONCOLOGY: HOW CLOSE ARE WE? {Ballroom 1}
Success in developing cell-based immunotherapies to treat cancer can only be measured through robust and compelling clinical outcomes. This panel will discuss how the sector is progressing clinically and what to expect in the next 2-3 years as more companies enter advanced clinical development with several filing for regulatory approval. The session will also explore the potential for combination treatments using cell-based approaches with other immunomodulatory therapies.
Sponsored by Thermo Fisher Scientific
Chair:
Amy Butler, Ph.D., VP and General Manager, Cell Biology, Thermo Fisher Scientific
Speakers:
Stewart Abbot, Ph.D., Chief Development Officer, Fate Therapeutics
David Chang, M.D., Ph.D., Chief Medical Officer and EVP, Research and Development, Kite Pharma
Thomas Farrell, President and CEO, Bellicum Pharmaceuticals
Christian Homsy, M.D., CEO, Celyad
10:15am – 10:30am | MORNING BREAK
Sponsored by Capricor Therapeutics and Terumo BCT
10:30am – 12:00pm | CONCURRENT TRACKS
GENE EDITING INTERVIEW {Ballroom 1}
10:30am – 11:15am
Gene editing, including CRISPR/Cas, TALENs, Zinc Finger Nucleases and other approaches, represents the ability to treat and potentially cure genetic disorders and other forms of disease by inserting, replacing or removing DNA using “molecular scissors,” or artificially engineered gene constructs. This interview will explore the current state of the science and both near-term and longer-term clinical and research applications.
Chair:
Blythe Thomson, M.D., Senior Director, Medical Affairs, Hematology and Oncology, Medpace
Speakers:
Alexandra Glucksmann, Ph.D., Chief Operating Officer, Editas Medicine
Sandy Macrae, Ph.D., President and CEO, Sangamo BioSciences
Prashant Mali, Ph.D., Assistant Professor, Department of Bioengineering, UC San Diego
COMPANY PRESENTATIONS {Ballroom 2}
10:30am – 10:45am Caladrius Biosciences
10:45am – 11:00am Nohla Therapeutics
11:00am – 11:15am GenVec
11:15am – 11:30am Abeona Therapeutics
11:30am – 11:45am NovaHep
11:45am – 12:00pm Juventas Therapeutics
COMPANY PRESENTATIONS {Ballroom 1}
11:15am – 11:30am Celyad
11:30am – 11:45am Mesoblast
11:45am – 12:00pm Capricor Therapeutics
12:00pm – 1:15pm | LUNCH
Sponsored by Lonza
1:15pm – 3:30pm | CONCURRENT TRACKS
PANEL: THE IMPACT OF A NEW HEALTHCARE MODEL: WHAT DO PAYERS THINK OF GENE THERAPIES? {Ballroom 1}
1:15pm – 2:15pm
Gene therapies offer potentially curative treatments to alleviate unmet need and improve patient outcomes. Cost and uncertain financing, however, present challenges to patient access. This panel will discuss the unique challenges presented by gene therapies with the current financing and reimbursement mechanisms and processes. As well, the panel will explore the impact these potentially curative therapies have on the current healthcare model designed to manage chronic diseases. This session will elevate the discussion from theoretical to the more practical considerations within existing or proposed financing models.
Sponsored by Quintiles
Chair:
John Doyle, Dr.P.H., SVP, Advisory Services, Quintiles
Speakers:
Nick Crabb, Ph.D., Programme Director – Scientific Affairs, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE)
Michael Fine, M.D., Medical Director, Health Net
Mark Trusheim, Founder and President, Co-Bio Consulting; Visiting Scientist, MIT Sloan School of Management
COMPANY PRESENTATIONS {Ballroom 2}
1:15pm – 1:30pm MaxCyte
1:30pm – 1:45pm 4D Molecular Therapeutics
1:45pm – 2:00pm Synpromics
2:00pm – 2:15pm ToolGen
COMPANY PRESENTATIONS {Ballroom 1}
2:15pm – 2:30pm ReNeuron
2:30pm – 2:45pm Oxford BioMedica
2:45pm – 3:00pm AGTC
3:00pm – 3:15pm GenSight Biologics
3:15pm – 3:30pm Audentes Therapeutics
COMPANY PRESENTATIONS {Ballroom 2}
2:15pm – 2:30pm Precision Biosciences
2:30pm – 2:45pm Universal Cells
2:45pm – 3:00pm Commence Bio
3:00pm – 3:15pm TxCell
3:15pm – 3:30pm Terumo BCT
3:30pm – 4:00pm | AFTERNOON BREAK
Sponsored by Capricor Therapeutics and Terumo BCT
4:00pm – 6:00pm | CONCURRENT TRACKS
PANEL: FINANCING GENE AND CELL THERAPY COMPANIES: THE INVESTOR’S PERSPECTIVE {Ballroom 1}
4:00pm – 5:00pm
While the financing window has closed for large portions of the technology sector, there still appears to be an appetite for gene and cell therapy companies with strong technology platforms and a well-defined clinical pathway to treat rare genetic disorders or change the standard of care in disease areas such as cancer or neurodegenerative diseases. This panel of investors will discuss the current financing climate for early- and clinical-stage companies and what has changed over the last two years.
Chair:
Reni Benjamin, Ph.D., SVP, Equity Research, Biotechnology, Raymond James
Speakers:
Racquel Bracken, VP, Venrock
Rowan Chapman, Ph.D., Head of Healthcare Investing, GE Ventures
David Kabakoff, Ph.D., Executive Partner, Sofinnova Ventures
Deval Lashkari, Ph.D., Senior Partner, Telegraph Hill Partners
Joseph Sum, Director of Research, EcoR1 Capital
COMPANY PRESENTATIONS {Ballroom 2}
4:00pm – 4:15pm Irvine Scientific
4:15pm – 4:30pm StemBioSys
4:30pm – 4:45pm CTI Clinical Trial & Consulting Services
4:45pm – 5:00pm Vitruvian Networks
COMPANY PRESENTATIONS {Ballroom 1}
5:00pm – 5:15pm Organovo
5:15pm – 5:30pm Histogenics
5:30pm – 5:45pm Osiris Therapeutics
5:45pm – 6:00pm Vericel Corporation
COMPANY PRESENTATIONS {Ballroom 2}
5:00pm – 5:15pm Cryoport Systems
5:15pm – 5:30pm Regencor
5:30pm – 5:45pm Cells for Cells
5:45pm – 6:00pm Stem Cell & Device Laboratory
6:00pm | PARTNERING CLOSES
6:30pm – 9:30pm | GALA RECEPTION
Sponsored by CCRM and Dohmen Life Science Services

CGMOM16-Agenda-Day2-495x105

7:00am – 9:30am | REGISTRATION AND BREAKFAST
Sponsored by MilliporeSigma
7:15am – 8:45am | CONCURRENT WORKSHOPS

ADDRESSING UNCERTAINTY IN REGENERATIVE MEDICINE VALUE DEMONSTRATION WORKSHOP

Magnolia Room | 7:15am – 8:45am

ADDRESSING UNCERTAINTY IN REGENERATIVE MEDICINE VALUE DEMONSTRATION WORKSHOP
What is Mission Critical vs. Mission Impossible?

Early payer evaluations of regenerative therapies have identified uncertainty in value demonstration as the most important global acceptance barrier. What are the core areas of payer uncertainty critical for regenerative medicine developers to address? Where have past technologies fallen short? What examples from the marketplace highlight successes and point to solutions to bridge the uncertainty chasm? How should approaches differ between rare versus common diseases? What solutions may work across highly variable global reimbursement systems? This panel will debate the implications of regenerative and potentially curative therapies and consider how regenerative medicine developers can overcome the uncertainty gaps associated with these technologies.

Chair:
Eric Faulkner, VP, Precision and Transformative Technology Solutions, Evidera

Speakers:
Craig Cheetham, Pharm.D., Research Scientist II, Department of Research and Evaluation, Kaiser Permanente Southern California
Dawn Driscoll, Ph.D., CEO, Isopogen
Donald Han, VP, Payer Insights and Access, Rare Disease, Global Health and Value, Pfizer
Panos Kefalas, Ph.D., Head of Health Economics and Market Access, Cell and Gene Therapy Catapult

PROCESS IMPROVEMENT AND ACCELERATED CMC DEVELOPMENT WORKSHOP

Learning Theater | 7:15am – 8:45am
Sponsored by PCT, A Caladrius Company and GE Healthcare

PROCESS IMPROVEMENT AND ACCELERATED CMC DEVELOPMENT WORKSHOP

The objective of this workshop is to discuss the needs of continuous process improvement for cell therapy manufacturing compared to major process changes for traditional drug/biologic manufacturing, the thinking or rethinking on comparability assessment and the need for potential regulatory mechanisms to help with accelerated CMC development to match accelerated clinical development under various existing regulatory pathways (conditional approval etc.).

7:15am – 7:25am | Introduction and Opening Remarks
Speaker:
Robert Preti, Ph.D., Chairman, Alliance for Regenerative Medicine (ARM); President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences

7:25am – 8:00am | Panel Discussion: Process Improvement and Comparability Assessment
Chair:
Robert Preti, Ph.D., Chairman, Alliance for Regenerative Medicine (ARM); President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences

8:00am – 8:35am | Panel Discussion: Accelerated CMC Development
Chair:
Jiwen Zhang, Ph.D., Senior Director, Regulatory Affairs, Cell Therapy and Regenerative Medicine, GE Healthcare

8:35am – 8:45am | Closing Remarks and Takeaways
Speaker:
Michael Mendicino, Ph.D., Owner and Chief Consultant/Advisor, Hybrid Concepts International

Expert Panelists from Regulatory Agencies:
Nicolas Ferry, M.D., Ph.D., Former Member, Committee for Advanced Therapies (CAT), European Medicines Agency (EMA); Founder and President, NF Consulting
Steven S. Oh, Ph.D., Chief, Cell Therapies Branch, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
Yoshiaki Maruyama, Ph.D., Review Director, Office of Cellular and Tissue-based Products (OCTP), Pharmaceuticals and Medical Devices Agency (PMDA)

Expert Panelists from Industry:
Stewart Abbot, Ph.D., Chief Development Officer, Fate Therapeutics
Francis Meacle, Ph.D., Director, Cell Therapy Manufacturing, Janssen R&D
Keith Wonnacott, Ph.D., Director, Regulatory Affairs, Novartis

 

9:00am | GENERAL SESSION AND PARTNERING OPENS
9:00am – 9:15am WELCOME REMARKS {Ballroom 1}
— ARM Annual Membership Meeting to Approve 2017 Board of Directors and Officers
Speakers:
Morrie Ruffin, Managing Director, Alliance for Regenerative Medicine (ARM)
Michael Werner, Executive Director, Alliance for Regenerative Medicine (ARM)
REGENERATIVE MEDICINE: REVOLUTIONIZING MEDICAL TREATMENT {Ballroom 1}
9:15am – 9:45am
Speaker:
Yuzo Toda, Chairman, Forum for Innovative Regenerative Medicine (FIRM); Senior Executive VP and Chief Technical Officer, Director, FUJIFILM Corporation
Moderated Discussion By:
Robert Preti, Ph.D., Chairman, Alliance for Regenerative Medicine (ARM); President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences
COMPANY PRESENTATIONS {Ballroom 2}
9:15am – 9:30am Fibrocell
9:30am – 9:45am Cellular Dynamics International
9:45am – 10:00am TrakCel
10:00am – 10:15am Thermo Fisher Scientific
AN UPDATE ON THE OFFICE OF CELLULAR, TISSUE AND GENE THERAPIES {Ballroom 1}
9:45am – 10:15am
Speaker:
Celia Witten, M.D., Ph.D., Deputy Director, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
10:15am – 10:45am | MORNING BREAK
Sponsored by Capricor Therapeutics and Terumo BCT
10:45am – 11:45am | CONCURRENT TRACKS
PANEL: EVOLVING REGULATORY SCIENCE TO SUPPORT INNOVATION {Ballroom 1}
10:45am – 11:45am
Improvement in Current Regulatory Processes for Cell and Gene Therapy Products
This panel will focus on key lessons learned from recent initiatives that have been put in place by regulators in different regions to accelerate the development of medicinal products, including cell and gene therapy products, as well as how existing regulatory processes could be improved further to support innovation in this field. The session will also include how international synergies could further support these types of innovations.
Sponsored by Cell and Gene Therapy Catapult and Janssen R&D
Chair:
Anne-Virginie Eggimann, VP, Regulatory Science, bluebird bio
Speakers:
Nicolas Ferry, M.D., Ph.D., Former Member, Committee for Advanced Therapies (CAT), European Medicines Agency (EMA); Founder and President, NF Consulting
Soichiro Isobe, Ph.D., Director, Medical Device Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, Government of Japan
Christiane Niederlaender, Ph.D., Senior Quality Assessor and Deputy Unit Manager, Biologicals Unit, Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA)
Celia Witten, M.D., Ph.D., Deputy Director, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
COMPANY PRESENTATIONS {Ballroom 2}
10:45am – 11:00am Cynata Therapeutics
11:00am – 11:15am TiGenix
11:15am – 11:30am Pluristem Therapeutics
11:30am – 11:45am Healios
11:45am – 1:00pm | LUNCH
Sponsored by Cellular Dynamics International
1:00pm – 2:45pm | CONCURRENT TRACKS
COMPANY PRESENTATIONS {Ballroom 1}
1:00pm – 1:15pm Sangamo BioSciences
1:15pm – 1:30pm bluebird bio
1:30pm – 1:45pm Editas Medicine
1:45pm – 2:00pm Intellia Therapeutics
2:00pm – 2:15pm Dimension Therapeutics
2:15pm – 2:30pm Voyager Therapeutics
2:30pm – 2:45pm Ventrix
COMPANY PRESENTATIONS {Ballroom 2}
1:00pm – 1:15pm Orchard Therapeutics
1:15pm – 1:30pm ViaCyte
1:30pm – 1:45pm Semma Therapeutics
1:45pm – 2:00pm MEDIPOST America
2:00pm – 2:15pm ORIG3N
2:15pm – 2:30pm Calimmune
2:30pm – 2:45pm Immusoft
2:45pm – 3:15pm | AFTERNOON BREAK
Sponsored by Capricor Therapeutics and Terumo BCT
3:15pm – 5:00pm | CONCURRENT TRACKS
PANEL: GENE THERAPY: COMMERCIALIZING A THERAPEUTIC PRODUCT {Ballroom 1}
3:15pm – 4:15pm
This panel will discuss aspects of the commercialization process that are unique to the gene therapy sector. Discussion will include market access issues, how companies are assembling commercially and what types of partnerships are available for these organizations.
Chair:
Alison Finger, SVP, Commercialization, bluebird bio
Speakers:
Andrea Hunt, VP, New Product Therapeutic Area Lead Gene Therapy, Neuroscience and Ophthalmology, Shire
Sven Kili, M.D., VP and Head of Gene Therapy Development, GlaxoSmithKline
Matt Patterson, President and CEO, Audentes Therapeutics
Sue Washer, President and CEO, AGTC
Elizabeth White, Ph.D., Assistant VP, Early Commercial Planning, Rare Disease and Gene Therapy, Pfizer Innovative Health
COMPANY PRESENTATIONS {Ballroom 2}
3:15pm – 3:30pm Biostage
3:30pm – 3:45pm Avita Medical
3:45pm – 4:00pm DiscGenics
4:00pm – 4:15pm InVivo Therapeutics
COMPANY PRESENTATIONS {Ballroom 1}
4:15pm – 4:30pm MolMed
4:30pm – 4:45pm Argos Therapeutics
4:45pm – 5:00pm Kiadis Pharma
COMPANY PRESENTATIONS {Ballroom 2}
4:15pm – 4:30pm Scottish National Blood Transfusion Service
4:30pm – 4:45pm Promethera Biosciences
4:45pm – 5:00pm SCM Lifescience
5:00pm | PARTNERING CLOSES

CGMOM16-Agenda-Day2-PF-592x105

5:30pm | PUBLIC FORUM OPENS
5:45pm – 6:45pm STEM CELLS, A HISTORY OF FREEDOM, HOPE AND REALITY
Introduction By:
Donna Skerrett, M.D., Chief Medical Officer, Mesoblast
Speaker:
Elena Cattaneo, Ph.D., Full Professor, Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases, Department of Biosciences, University of Milan
6:45pm – 7:30pm | RECEPTION AND NETWORKING
Sponsored by Mesoblast
7:30pm | PUBLIC FORUM CLOSES

CGMOM16-Agenda-Day3-530x105

7:00am – 8:00am | REGISTRATION AND BREAKFAST
Sponsored by Sanford Stem Cell Clinical Center
8:00am | GENERAL SESSION
8:00am – 8:15am WELCOME REMARKS
Speaker:
Alysson Muotri, Ph.D., Chair, Scientific Symposium Steering Committee; Co-Director, Stem Cell Program; Associate Professor, Department of Pediatrics and Cellular Molecular Medicine, UC San Diego
8:15am – 8:55am STEM CELL-BASED THERAPY FOR PARKINSON’S DISEASE
Sponsored by HemaCare
Keynote Speaker:
Jun Takahashi, M.D., Ph.D., Professor, Center for iPS Cell Research and Application (CiRA), Kyoto University
8:55am – 10:15am PANEL: ORGANOIDS IN A DISH
Human pluripotent stem cells can be used to generate different types of cells in a dish. Recently, this technology has evolved to produce organoids, tridimensional self-assemble structures that possess certain features of human tissues, including the spatial organization of multi-cellular systems. Organoids could serve as unprecedentedly accurate models of study for a wide range of human diseases. This session will highlight recent advances on the use of this technology to gain novel insights into human development.
Chair / Introduction By:
Alysson Muotri, Ph.D., Co-Director, Stem Cell Program; Associate Professor, Department of Pediatrics and Cellular Molecular Medicine, UC San Diego
Brain Organoids as a Model for Neurological Diseases
Alysson Muotri, Ph.D., Co-Director, Stem Cell Program; Associate Professor, Department of Pediatrics and Cellular Molecular Medicine, UC San Diego
Comparative Analysis of Human and Mouse Nephron Formation to Inform In Vitro Nephrogenesis
Trinh (Tracy) Tran, Ph.D. Candidate, The McMahon Laboratory, Keck School of Medicine, University of Southern California (USC)
In Vivo and In Vitro Approaches to Regenerative Medicine
Juan Carlos Izpisua Belmonte, Ph.D., Professor, Gene Expression Laboratory; Roger Guillemin Chair, Salk Institute for Biological Studies
10:15am – 10:40am | MORNING BREAK
Sponsored by Capricor Therapeutics and Terumo BCT
10:15am – 10:40am | POSTER VIEWING – EVEN NUMBER ABSTRACTS
10:40am – 12:00pm PANEL: CELL THERAPY FOR HEMATOPOIETIC DISORDERS AND BEYOND
This session will cover recent advances in hematopoietic cell transplantation, cellular immunotherapies and combination therapies with cells. The panel will also discuss therapeutic approaches to better treat both hematologic malignancies and solid tumors.
Chair / Introduction By:
Dan Kaufman, M.D., Ph.D., Director, Cell Therapy Program; Professor, Department of Medicine, UC San Diego
To Be Determined
Claudio Brunstein, M.D., Ph.D., Associate Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota
Recent Advances in Cellular Immunotherapy
Dan Kaufman, M.D., Ph.D., Director, Cell Therapy Program; Professor, Department of Medicine, UC San Diego
Novel Cancer Immunotherapeutics: New Targets, New Combinations
Sandip Patel, M.D., Assistant Professor, Medical Oncology/Hematology, UC San Diego Moores Cancer Center
12:00pm – 1:15pm | LUNCH
Sponsored by Sanford Stem Cell Clinical Center
12:00pm – 1:15pm | POSTER VIEWING – ODD NUMBER ABSTRACTS
1:15pm – 2:35pm PANEL: GENOMICS AND GENETICS
Recent technological advances have uncovered new fundamental mechanisms of gene expression regulation. This session covers some of the most exciting findings: from the shape of the genome to the surprisingly diverse roles of non-coding RNAs.
Chair / Introduction By:
Stefan Aigner, Ph.D., Project Scientist, Department of Cellular and Molecular Medicine, UC San Diego
Cracking the Nucleus: Visualizing the Higher Order 3D Coding Structures of DNA
Clodagh O’Shea, Ph.D., Associate Professor, Molecular and Cell Biology Laboratory; William Scandling Developmental Chair, Salk Institute for Biological Studies
Regulating T Helper 17 Immunity: From Serum Amyloid to RNA Helicase and its Associated Long Non-coding RNAs
Wendy Huang, Ph.D., Assistant Professor, Department of Cellular and Molecular Medicine, School of Medicine, UC San Diego
Illuminating the Dark Side of the MicroRNA
Amy Pasquinelli, Ph.D., Professor of Biology, Molecular Section, UC San Diego
2:35pm – 3:00pm | AFTERNOON BREAK
Sponsored by Capricor Therapeutics and Terumo BCT
2:35pm – 3:00pm | POSTER VIEWING – EVEN NUMBER ABSTRACTS
3:00pm – 4:20pm PANEL: UNBIASED DISCOVERY METHODS IN THE DEVELOPMENT OF CELL-BASED THERAPIES
This session will focus on the use of stem/progenitor cell- and iPS cell-based systems for drug discovery, as well as high throughput discovery-based methods for elucidating novel mechanisms and targets related to stem cells and cell fate. Topics will include CRISPR-based cell engineering, RNA splicing and patient cell-based drug discovery.
Co-Chairs / Introduction By:
Anne Bang, Ph.D., Director, Cell Biology, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys (SBP) Medical Discovery Institute
Luke Lairson, Ph.D., Assistant Professor, Department of Chemistry, The Scripps Research Institute (TSRI); Director, High Throughput Discovery and Principal Investigator, California Institute for Biomedical Research (Calibr)
New Mechanistic Insights into Leukemia Caused by Mutations in Splicing Factor
Xiang-Dong Fu, Ph.D., Professor, Cellular and Molecular Medicine, UC San Diego
CRISPR-Cas Systems as Versatile Tools for Engineering Biology
Prashant Mali, Ph.D., Assistant Professor of Bioengineering, UC San Diego
New Insights into Neurodegenerative Disease Processes
Lee Rubin, Ph.D., Professor, Stem Cell and Regenerative Biology, Harvard University; Director of Translational Medicine, Harvard Stem Cell Institute
4:20pm – 5:00pm HUMAN PLURIPOTENT DERIVED LINEAGES FOR CNS AND PNS REPAIR
Sponsored by Voyager Therapeutics
Keynote Speaker:
Lorenz Studer, M.D., Ph.D., Director, Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center
5:00pm – 6:30pm | NETWORKING RECEPTION
Sponsored by Sanford Stem Cell Clinical Center
5:00pm – 6:30pm | POSTER VIEWING – ALL POSTERS
6:30pm | SCIENTIFIC SYMPOSIUM CLOSES